



For Immediate Release

United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report

Report available at corporateresponsibility.unither.com

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 12, 2023 -- United Therapeutics Corporation (Nasdaq: **UTHR**), a public benefit corporation (**PBC**), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of its patients and other stakeholders.

As a PBC, United Therapeutics is obligated to report its progress toward its public benefit purpose – to *provide a brighter future for patients through the development of novel pharmaceutical therapies, and technologies that expand the availability of transplantable organs*. It pursues this purpose alongside its obligations to balance the interests of its other stakeholders, including employees, local communities, investors, and the greater ecosystem in which it operates. This is the first full year United Therapeutics is reporting its progress against its public benefit goals and objectives established in 2021, aligned with its three core stakeholder groups – what the company calls *Our Patients, Our People, and Humankind*.

The company reported that as of the end of 2022, it was serving more than 12,500 patients on its therapies. “Patient outcomes are our top priority,” said **James Edgemond**, Chief Financial Officer and Treasurer of United Therapeutics. “We also know patient outcomes are inextricably linked to the other domains of our PBC goals. For example, we need smart, committed, passionate people to do this work, and we need to steward our resources – human, financial, and environmental – to get better, long-lasting outcomes.”

Underscoring this point, some of the progress metrics United Therapeutics reports include very low voluntary turnover – 9% compared to an almost-15% industry average – and the [opening](#) of a first of its kind site net zero cold storage current Good Manufacturing Practices warehouse in North Carolina in 2023. This is the fifth site net zero facility in the company’s portfolio, which altogether represent about 16% of the portfolio’s square footage.

“We have taken what we know are leading actions in terms of the environmental footprint of our facilities,” said **Christopher Causey**, Chair of the Nominating and Governance Committee of the United Therapeutics Board of Directors. “And still, as our CEO Dr. **Martine Rothblatt** says in her opening message of the report, we understand there is more work ahead. We are committed to taking meaningful, evidence-based actions that we look forward to sharing with our stakeholders as we continue forward.”

Find the full report at corporateresponsibility.unither.com.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to *provide a*

brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/PBC.

Forward-looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding progress toward achieving our public benefit purpose and the interests of other stakeholders (including employees, local communities, investors, and the greater ecosystem in which we operate), our efforts to steward our resources – human, financial, and environmental – to get better, long-lasting outcomes, our commitment to taking meaningful, evidence-based actions, and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders and furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 12, 2023, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

For Further Information Contact:

Catherine Sheehy at (240) 398-3504 (sustainability)

Dewey Steadman at (202) 919-4097 (investors/media)